Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 6/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 9/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22611888 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2NPSR1ALDH1A1KMT2ALMNA | |
| SCHEMBL15331979 | 0.81 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1KMT2ALMNAPOLB | |
| SCHEMBL15330789 | 0.77 | NPSR1 (0.51) | SMN1; SMN2NPSR1ALDH1A1KMT2ALMNA | |
| SCHEMBL29950777 | 0.77 | SMN1; SMN2 (0.58) | SMN1; SMN2NPSR1ALDH1A1KMT2ALMNA | |
| SCHEMBL13488596 | 0.77 | NPSR1 (0.66) | SMN1; SMN2NPSR1ALDH1A1KMT2ALMNA | |
| SCHEMBL7293758 | 0.75 | LMNA (0.56) | SMN1; SMN2NPSR1ALDH1A1KMT2ALMNA | |
| SCHEMBL7290595 | 0.75 | NPSR1 (0.53) | SMN1; SMN2NPSR1ALDH1A1KMT2ALMNA | |
| SCHEMBL15331397 | 0.74 | ALDH1A1 (0.58) | SMN1; SMN2NPSR1ALDH1A1KMT2ALMNA | |
| SCHEMBL6468905 | 0.73 | NPSR1 (0.52) | SMN1; SMN2NPSR1ALDH1A1KMT2ALMNA | |
| SCHEMBL5322133 | 0.73 | NPSR1 (0.51) | SMN1; SMN2NPSR1ALDH1A1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10676484-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA FARBER CANCER INST INC (US) | 2020-05-14 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | DANA-FARBER CANCER INSTITUTE, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | DANA-FARBER CANCER INSTITUTE, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130184264-A1 | Compositions And Methods For Treating Neoplasia, Inflammatory Disease And Other Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-07-18 | — | — | US | disclosed |
| US-20120126690-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE | FUJIFILM CORPORATION | 2012-05-24 | — | — | US | disclosed |
| US-20080153855-A1 | Thieno[2,3-d]pyrimidinedione derivatives; antiproliferative agents against T-cells; chronic obstructive pulmonary disease, asthma; immunosuppressants, antihistamines, bronchodilator agents, and anticarcinogenic agents | ASTRAZENECA AB, A SWEDEN CORPORATION | 2008-06-26 | — | — | US | disclosed |
| US-7361660-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2008-04-22 | — | — | US | disclosed |
| EP-1412362-B1 | THIENO¬2,3-d|PYRIMIDINEDIONES AS INHIBITORS OF T-CELLS PROLIFERATION | ASTRAZENECA AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| US-20040171623-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2004-09-02 | — | — | US | disclosed |
| EP-1412362-A1 | CHEMICAL COMPOUNDS | Astrazeneca AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003008422-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | SMN1; SMN2 4177/4885NPSR1 3994/4885ALDH1A1 2424/4885 |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | BRPF3, EP300, BRD3 | SMN1; SMN2 4030/4885NPSR1 4603/4885ALDH1A1 3670/4885 |
| US-10676484-B2 | Compositions and methods for treating leukemia | MCL1, ABL1, FLT3 | SMN1; SMN2 2078/4885NPSR1 4356/4885ALDH1A1 1723/4885 |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | SHBG, CYP19A1, CYP17A1 | SMN1; SMN2 4353/4885NPSR1 550/4885ALDH1A1 1692/4885 |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | MCL1, ABL1, FLT3 | SMN1; SMN2 2078/4885NPSR1 4356/4885ALDH1A1 1723/4885 |
| US-20080153855-A1 | Thieno[2,3-d]pyrimidinedione derivatives; antiproliferative agents against T-cells; chronic obstructive pulmonary disease, asthma; immunosuppressants, antihistamines, bronchodilator agents, and anticarcinogenic agents | HRH4, HRH2, HRH3 | SMN1; SMN2 4492/4885NPSR1 926/4885ALDH1A1 463/4885 |
| US-20130184264-A1 | Compositions And Methods For Treating Neoplasia, Inflammatory Disease And Other Disorders | BRPF3, EP300, BRD3 | SMN1; SMN2 4030/4885NPSR1 4603/4885ALDH1A1 3670/4885 |
| US-20040171623-A1 | Chemical compounds | CBR1, SETDB1, CBR3 | SMN1; SMN2 3624/4885NPSR1 1811/4885ALDH1A1 401/4885 |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | BRPF3, EP300, BRD3 | SMN1; SMN2 4030/4885NPSR1 4603/4885ALDH1A1 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.